Search peptides, terms, sources/
Glossary

NICE Technology Appraisal

A formal assessment by the National Institute for Health and Care Excellence (NICE) of whether a licensed medicine should be routinely funded and offered by the NHS in England, based on how well it works and whether it is good value for the NHS. A positive NICE technology appraisal is a separate step from MHRA licensing: a medicine can hold a UK marketing authorisation without yet being routinely available on the NHS for a given use, and the two decisions can happen on different timelines.

Peptides where this matters

  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Tirzepatide

    Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine

All glossary terms

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.